Ligand Pharmaceuticals (LGND) Operating Margin (2016 - 2025)
Historic Operating Margin for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to 47.58%.
- Ligand Pharmaceuticals' Operating Margin rose 415100.0% to 47.58% in Q3 2025 from the same period last year, while for Sep 2025 it was 6.97%, marking a year-over-year increase of 176900.0%. This contributed to the annual value of 13.53% for FY2024, which is 226200.0% down from last year.
- Latest data reveals that Ligand Pharmaceuticals reported Operating Margin of 47.58% as of Q3 2025, which was up 415100.0% from 17.73% recorded in Q2 2025.
- In the past 5 years, Ligand Pharmaceuticals' Operating Margin registered a high of 66.82% during Q4 2021, and its lowest value of 79.89% during Q1 2025.
- Moreover, its 5-year median value for Operating Margin was 9.65% (2024), whereas its average is 6.32%.
- In the last 5 years, Ligand Pharmaceuticals' Operating Margin plummeted by -1067100bps in 2022 and then skyrocketed by 637200bps in 2025.
- Ligand Pharmaceuticals' Operating Margin (Quarter) stood at 66.82% in 2021, then tumbled by -160bps to 39.89% in 2022, then soared by 70bps to 11.95% in 2023, then crashed by -88bps to 22.51% in 2024, then soared by 311bps to 47.58% in 2025.
- Its Operating Margin stands at 47.58% for Q3 2025, versus 17.73% for Q2 2025 and 79.89% for Q1 2025.